Full-Time

Director/Senior Director

Government Accounts, Nation

Stoke Therapeutics

Stoke Therapeutics

201-500 employees

Develops targeted gene upregulation therapies

Compensation Overview

$238k - $322k/yr

+ Bonus + Equity

Bedford, MA, USA

Hybrid

Relocation to Waltham, Massachusetts may be required; remote/field-based with ~50% travel to state agencies and meetings.

Category
Medical, Clinical & Veterinary (1)

Get referred to Stoke Therapeutics

See people who can refer or advise you

Requirements
  • Bachelor's degree required; advanced degree (MBA, PharmD, MPH) strongly preferred.
  • 15+ years in pharma/biotech; minimum 8 years in government or Medicaid payer account management.
  • Pre-launch government payer strategy experience—not just maintenance of established access.
  • Hands-on experience navigating the miscellaneous J code environment (J3490/J3590) within Medicaid, including payer education on NDC crosswalk requirements, claims-level billing guidance, and coordination with FRMs and specialty distribution in a Medicaid context.
  • Rare pediatric or rare neurological disease product launch experience; CNS or epilepsy payer experience a significant differentiator.
  • Familiarity with 340B program intersections for rare disease products and duplicate discount compliance.
  • Experience navigating Medicaid disability transition pathways (SSI/SSDI) for pediatric-onset neurological disease populations.
  • Experience at a company building its commercial infrastructure for the first time—startup or early commercial-stage biotech.
Responsibilities
  • Develop and execute pre-launch and launch-phase access strategies across Medicaid FFS and Managed Medicaid, establishing Stoke’s credibility with state agencies ahead of FDA approval.
  • Serve as Stoke’s primary relationship owner and strategic point of contact across state Medicaid pharmacy and medical directors, DUR/P&T board members, and Managed Medicaid MCO leaders in priority states.
  • Maintain a deep understanding of account-level policies, state drug review processes, competitive dynamics, decision timelines, and state priorities impacting access.
  • Develop multi-year state Medicaid access plans that anticipate policy shifts, IRA pricing dynamics, and competitive changes, balancing state-by-state tactical execution with a national access strategy.
  • Proactively engage state Medicaid medical and pharmacy directors to secure informal billing guidance, coverage letters, or favorable fee-for-service payment determinations ahead of a permanent J code assignment.
  • Monitor AMP-based reimbursement benchmarks, Medicaid Upper Payment Limits (UPLs), and state-specific drug fee schedules to provide payers with accurate, transparent pricing narratives that support appropriate reimbursement under the medical benefit.
  • Monitor federal and state Medicaid policy developments—including CMS guidance, CMCS informational bulletins, state plan amendments (SPAs), and 1115/1915 waiver activity—and translate implications for brand access strategy.
  • Educate government payers on clinical and economic value in frameworks meaningful to state Medicaid budget and policy decision-makers.
  • Educate Stoke’s patient services and field reimbursement teams on navigating the miscellaneous J code environment at launch, including NDC crosswalk requirements and Medicaid-specific billing procedures.
  • Serve as the internal subject-matter expert on Medicaid reimbursement dynamics for medical benefit products carrying a miscellaneous J code (J3490/J3590) pending assignment of a permanent, product-specific code.
  • Lead cross-functional collaboration with Policy, Advocacy, HEOR, Reimbursement, Trade & Distribution, and Marketing partners to advance access goals and account-level execution.
  • Coordinate pull-through activities with Stoke’s field teams, patient services, and reimbursement teams to ensure coverage decisions translate to patient access.
  • Synthesize complex CMS guidance, state legislative changes, and IRA pricing developments into clear, actionable implications for the business, communicating effectively from field teams to executive leadership.
  • Engage authentically with the Dravet syndrome patient and caregiver community and incorporate community insights into government payer engagement in a compelling and compliant manner.
  • Conduct all government account engagements in full compliance with company SOPs, OIG guidelines, PhRMA Code, the Anti-Kickback Statute, and applicable federal and state Medicaid regulations.
  • Navigate the unique complexity of a first-in-class disease-modifying ASO therapy with no established Medicaid coverage precedent, finding creative and compliant paths to access.

Stoke Therapeutics develops therapies for severe genetic diseases caused by loss of function in a single gene, aiming to restore missing proteins by upregulating protein expression. Its main product approach relies on the TANGO (Targeted Augmentation of Nuclear Gene Output) platform, which delivers precise, durable, and controllable upregulation of gene expression across a range of tissues to re-create the missing protein. Compared with many biotech firms, Stoke centers on upregulating endogenous gene output rather than replacing genes or adding new ones, and focuses on disease-modifying treatments for rare disorders with unmet medical needs. Revenue comes from partnerships, licensing agreements, and, ultimately, commercialization of its therapies. The company’s goal is to provide targeted, durable treatments that address the underlying genetic deficiency and improve outcomes for patients with limited options.

Company Size

201-500

Company Stage

IPO

Headquarters

Bedford, Texas

Founded

2014

Get referred to Stoke Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Phase 3 EMPEROR enrollment completes Q2 2026, mid-2027 readout enables 2027 FDA filing.
  • $246.7M cash runway extends operations through mid-2028 post-Biogen $165M upfront.
  • NEJM publication validates multi-year seizure reductions and cognitive improvements in Dravet.

What critics are saying

  • Phase 3 failure to replicate Phase 1/2 efficacy erases $1.9B market cap existentially.
  • Biogen terminates collaboration, withdrawing $385M milestones needed for Phase 3 completion.
  • DNL343 small-molecule competitor demonstrates superior brain penetration and oral bioavailability.

What makes Stoke Therapeutics unique

  • TANGO platform enables durable, tissue-agnostic protein upregulation for genetic diseases.
  • Zorevunersen targets SCN1A loss-of-function, addressing Dravet syndrome's root cause.
  • Antisense oligonucleotide approach offers oral or feeding tube administration flexibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

3%

2 year growth

1%
Business Wire
Apr 7th, 2026
Stoke Therapeutics appoints Clare Kahn to board as Dravet syndrome treatment advances to Phase 3

Stoke Therapeutics has appointed Clare Kahn, PhD, to its Board of Directors. The Bedford, Massachusetts-based biotechnology company is developing zorevunersen, an investigational RNA medicine for Dravet syndrome, a severe genetic epilepsy. Dr Kahn brings over 30 years of pharmaceutical industry experience, most recently serving as R&D Strategy Officer at X-VAX Technology. She previously held senior positions at Pfizer and GlaxoSmithKline, with expertise in regulatory strategy and rare genetic disease development. The appointment comes as Stoke advances a Phase 3 clinical study of zorevunersen, which targets the underlying cause of Dravet syndrome. The company has a strategic collaboration with Biogen for the drug's development and commercialisation, retaining exclusive US, Canada and Mexico rights whilst Biogen holds rest-of-world rights.

Yahoo Finance
Mar 28th, 2026
Stoke Therapeutics chair sells $174K in shares as stock surges 340%

Stoke Therapeutics chair Arthur Tzianabos sold 4,355 shares of common stock for approximately $174,000 on 10th March 2026, according to an SEC Form 4 filing. The transaction resulted from exercising 3,955 stock options followed by an immediate sale. The sale reduced Tzianabos's direct common stock holdings by 12.20% to 31,339 shares. However, he continues to hold 118,696 stock options, maintaining significant potential future ownership. No indirect holdings through family trusts or LLCs were involved in the transaction. Stoke Therapeutics develops antisense oligonucleotide medicines targeting severe genetic diseases, with a market capitalisation of $1.9 billion. The company's lead clinical candidates include STK-001 for Dravet syndrome and STK-002 for autosomal dominant optic atrophy. The stock has risen 340% over one year.

Yahoo Finance
Mar 24th, 2026
Stoke Therapeutics CMO sells $457K in stock after 300% rally

Stoke Therapeutics chief medical officer Barry Ticho sold 14,311 shares of common stock for approximately $457,000 between 17 March and 19 March 2026, according to an SEC Form 4 filing. The sale price averaged $31.92 per share. The transaction reduced Ticho's direct holdings from 55,013 to 40,702 shares, a 26% decrease. He retains 83,035 stock options, giving him total beneficial interest of approximately 123,700 shares. The sale, which involved exercising options followed by immediate disposal, exceeded Ticho's historical median sale size of 7,073 shares. It occurred following a 300% one-year share price increase for the biotechnology company, which develops treatments for rare genetic neurological disorders. Stoke Therapeutics has a market capitalisation of $1.98 billion.

Yahoo Finance
Mar 7th, 2026
Stoke Therapeutics publishes Dravet syndrome trial data in NEJM, targets 2027 FDA filing

Stoke Therapeutics and Biogen announced that data on investigational Dravet syndrome treatment zorevunersen were published in The New England Journal of Medicine, showing multi-year seizure reductions and cognitive improvements. The company also updated its Phase 3 EMPEROR timeline, with enrollment completing by Q2 2026, mid-2027 readout, and plans to begin rolling FDA submission in the first half of 2027. The NEJM publication strengthens the biological rationale for zorevunersen's antisense platform. However, the key near-term catalyst remains whether the Phase 3 trial can confirm the long-term seizure and cognitive benefits observed thus far. Stoke's narrative projects $81.1 million revenue and $13.2 million earnings by 2028, implying a 26.7% yearly revenue decline. Optimistic analysts model 2028 revenue near $63.4 million.

ChartMill
Feb 4th, 2026
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Stoke Therapeutics to present at the Guggenheim Emerging Outlook: Biotech Summit 2026. Provided By Business Wire - Last update: Feb 4, 2026 Article Mentions: Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET. A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke Therapeutics Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/. About Zorevunersen Zorevunersen is an investigational antisense oligonucleotide that is designed to treat the underlying cause of Dravet syndrome by increasing functional NaV1.1 protein production in brain cells from the non-mutated (wild-type) copy of the SCN1A gene. This highly differentiated mechanism of action aims to reduce seizure frequency beyond what has been achieved with anti-seizure medicines and to improve neurodevelopment, cognition and behavior. Zorevunersen has demonstrated the potential for disease modification and has been granted orphan drug designation by the FDA and the EMA. The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function, in the SCN1A gene. Stoke has a strategic collaboration with Biogen (Nasdaq: BIIB) to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights.